Overview

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-nave Patients With Myelofibrosis

Status:
WITHDRAWN
Trial end date:
2025-05-09
Target enrollment:
Participant gender:
Summary
To assess INCB05643 + ruxolitinib JAKi-naive patients with myelofibrosis
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
ruxolitinib